Patent · US Active

Imidazopyridazinecarbonitriles useful as kinase inhibitors

US9371328B2 · kind B2 · utility

0Cited by

3References

8Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Brian E. Fink · Yardley, US
Libing Chen · Newtown, US
Ashvinikumar V. Gavai · Princeton Junction, US
Liqi He · West Chester, US
Soong-Hoon Kim · Titusville, US
Andrew James Nation · Scotch Plains, US
Yufen Zhao · Pennington, US
Litai H. Zhang · Lawrenceville, US

Key dates

Filing date	Feb 27, 2014
Grant date	Jun 21, 2016
Priority date	—
Expiry date	Feb 27, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compounds of Formula (I)and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.